Lobbying is building up to endorse CBD products for the treatment of pain and Opioid Use Disorder, from:
https://globenewswire.com/news-rele...rance-Companies-to-Cover-Cannabidiol-CBD.html
American Pain Association Spearheads Movement for Insurance Companies to Cover Cannabidiol (CBD)
Email Print Friendly Share
October 16, 2018 11:28 ET | Source: American Pain Association
BALA CYNWYD, Pa., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Dr. Sanjay Gupta, President of the American Pain Association ( APA and a pain management specialist based in Bala Cynwyd, Penn., is leading the push for insurance companies to cover the cost of cannabidiol (CBD) products for the treatment of pain and Opioid Use Disorder.“Simply put, CBD is marijuana (or cannabis) without THC, which is the psychoactive compound found in cannabis plants. CBD does not make patients high and is proving to have many health benefits,” Dr. Gupta said.
Dr. Gupta continued: “Additionally, CBD can help significantly in the opioid crisis the US is currently facing; however, given the cost and lack of insurance coverage, many patients are not able to afford it. Given the choice between Oxycontin, Percocet and CBD, patients are more likely to choose the narcotics because they are covered by insurance companies and are affordable with co-pays or even free of charge. Insurance companies should be open to paying for patients who are willing to reduce opioid use by using CBD. It would be much cheaper for insurance companies to cover CBD treatments compared to the costs of narcotic prescriptions and managing their side effects.”
CBD is a non-habit-forming compound that has recently been approved for epilepsy treatment in children by the FDA. Last week, a formulation approved by the FDA that includes CBD was re-classified by the Drug Enforcement Agency (DEA) to Schedule 5, given its proven health benefits. To further this movement, the APA has started a multi-institutional CBD research initiative and is partnering with faculty in seven medical schools and universities around the nation to obtain the research and data necessary to communicate the benefit of covering CBD products to the insurance companies.
Patients and companies who would like to participate in the studies are advised to email [email protected].
Dr. Gupta currently serves as President of the American Pain Association, an organization with board members from Harvard Medical School, Johns Hopkins Hospital and Weill Cornell Medicine, among other prestigious universities and medical schools.
With a focus on education and research-backed data, Dr. Gupta and the American Pain Association are working to make CBD an accessible form of pain treatment to patients locally and nationwide.
- Forums
- ASX - By Stock
- BOD
- Ann: Bod Achieves Word First in Phase 1 Clinical Trial
Ann: Bod Achieves Word First in Phase 1 Clinical Trial, page-16
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOD (ASX) to my watchlist
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
BOD (ASX) Chart |
Day chart unavailable
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online